Amylyx Pharmaceuticals (AMLX) shares were up 9.3% in Thursday trading after the company's net loss narrowed in Q2.
The company reported a quarterly net loss of $0.39 per diluted share, narrowing from a loss of $0.46 a year earlier.
Analysts polled by FactSet expected a loss of $0.36.
The company had cash, cash equivalents, and short-term investments of $250.8 million at June 30, expecting a cash runway into 2028.
Price: $23.87, Change: $+2.02, Percent Change: +9.24%